drugset

drugset / Trial / NCT07303907

A Phase 2A Trial of DT402 for Autism Spectrum Disorder

NCT07303907 ↗

Phase 2 Recruiting 20 enrolled Definium Therapeutics US, Inc.

NaSingle-groupOpen-labelTreatment

Summary

A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder

Timeline

Start: 2025-12-03
Primary completion: 2027-08
Completion: 2027-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DT402	Unknown	200 mg	—

Indications